A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Phase: Phase 4
Diagnosis: Gastrointestinal Malignancies
NCT ID: NCT01525550
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-210
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
Dana-Farber Cancer Institute, Brigham and Women's Hospital
Matthew Kulke, MD,
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute:
Gastrointestinal Research Line, 617-632-5960
- Histologically or cytologically proven diagnosis of well-differentiated pancreatic
neuroendocrine tumor (according to World Health Organization [WHO 2000]
- Disease progression within 12 months prior to study enrollment.
- Disease that is not amenable to surgery, radiation, or combined modality therapy with
- Patients with poorly differentiated pancreatic neuroendocrine tumors (according to
WHO 2000 classification).
- Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth
factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or
mammalian target of rapamycin (mTOR) inhibitors.